Cargando…
Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis
BACKGROUND: Liver transplantation (LT) is frequently lifesaving for people living with primary sclerosing cholangitis (PSC). However, patients are waitlisted for LT according to the model for end-stage liver disease-sodium (MELD-Na) score, which may not accurately reflect the burden of living with P...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552969/ https://www.ncbi.nlm.nih.gov/pubmed/37534935 http://dx.doi.org/10.1097/HC9.0000000000000219 |
_version_ | 1785116065304412160 |
---|---|
author | Onofrio, Fernanda Zheng, Katina Xu, Cherry Chen, Shiyi Xu, Wei Vyas, Mary Bingham, Katie Patel, Keyur Lilly, Leslie Cattral, Mark Selzner, Nazia Jaeckel, Elmar Tsien, Cynthia Gulamhusein, Aliya Hirschfield, Gideon M. Bhat, Mamatha |
author_facet | Onofrio, Fernanda Zheng, Katina Xu, Cherry Chen, Shiyi Xu, Wei Vyas, Mary Bingham, Katie Patel, Keyur Lilly, Leslie Cattral, Mark Selzner, Nazia Jaeckel, Elmar Tsien, Cynthia Gulamhusein, Aliya Hirschfield, Gideon M. Bhat, Mamatha |
author_sort | Onofrio, Fernanda |
collection | PubMed |
description | BACKGROUND: Liver transplantation (LT) is frequently lifesaving for people living with primary sclerosing cholangitis (PSC). However, patients are waitlisted for LT according to the model for end-stage liver disease-sodium (MELD-Na) score, which may not accurately reflect the burden of living with PSC. We sought to describe and analyze the clinical trajectory for patients with PSC referred for LT, in a mixed deceased donor/living donor transplant program. METHODS: This was a retrospective cohort study from November 2012 to December 2019, including all patients with PSC referred for assessment at the University Health Network Liver Transplant Clinic. Patients who required multiorgan transplant or retransplantation were excluded. Liver symptoms, hepatobiliary malignancy, MELD-Na progression, and death were abstracted from chart review. Competing risk analysis was used for timing of LT, transplant type, and death. RESULTS: Of 172 PSC patients assessed, 84% (n = 144) were listed of whom 74% were transplanted. Mean age was 47.6 years, and 66% were male. Overall mortality was 18.2% at 2 years. During the follow-up, 16% (n = 23) were removed from the waitlist for infection, clinical deterioration, liver-related mortality or new cancer; 3 had clinical improvement. At listing, 82% (n = 118) had a potential living donor (pLD). Patients with pLD had significantly lower waitlist and liver-related waitlist mortality (HR 0.20, p<0.001 and HR 0.17, p<0.001, respectively), and higher rates of transplantation (HR 1.83, p = 0.05). Exception points were granted to 13/172 (7.5%) patients. CONCLUSIONS: In a high-volume North American LT center, most patients with PSC assessed for transplant were listed and subsequently transplanted. However, this was a consequence of patients engaging in living donor transplantation. Our findings support the concern from patients with PSC that MELD-Na allocation does not adequately address their needs. |
format | Online Article Text |
id | pubmed-10552969 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-105529692023-10-06 Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis Onofrio, Fernanda Zheng, Katina Xu, Cherry Chen, Shiyi Xu, Wei Vyas, Mary Bingham, Katie Patel, Keyur Lilly, Leslie Cattral, Mark Selzner, Nazia Jaeckel, Elmar Tsien, Cynthia Gulamhusein, Aliya Hirschfield, Gideon M. Bhat, Mamatha Hepatol Commun Original Article BACKGROUND: Liver transplantation (LT) is frequently lifesaving for people living with primary sclerosing cholangitis (PSC). However, patients are waitlisted for LT according to the model for end-stage liver disease-sodium (MELD-Na) score, which may not accurately reflect the burden of living with PSC. We sought to describe and analyze the clinical trajectory for patients with PSC referred for LT, in a mixed deceased donor/living donor transplant program. METHODS: This was a retrospective cohort study from November 2012 to December 2019, including all patients with PSC referred for assessment at the University Health Network Liver Transplant Clinic. Patients who required multiorgan transplant or retransplantation were excluded. Liver symptoms, hepatobiliary malignancy, MELD-Na progression, and death were abstracted from chart review. Competing risk analysis was used for timing of LT, transplant type, and death. RESULTS: Of 172 PSC patients assessed, 84% (n = 144) were listed of whom 74% were transplanted. Mean age was 47.6 years, and 66% were male. Overall mortality was 18.2% at 2 years. During the follow-up, 16% (n = 23) were removed from the waitlist for infection, clinical deterioration, liver-related mortality or new cancer; 3 had clinical improvement. At listing, 82% (n = 118) had a potential living donor (pLD). Patients with pLD had significantly lower waitlist and liver-related waitlist mortality (HR 0.20, p<0.001 and HR 0.17, p<0.001, respectively), and higher rates of transplantation (HR 1.83, p = 0.05). Exception points were granted to 13/172 (7.5%) patients. CONCLUSIONS: In a high-volume North American LT center, most patients with PSC assessed for transplant were listed and subsequently transplanted. However, this was a consequence of patients engaging in living donor transplantation. Our findings support the concern from patients with PSC that MELD-Na allocation does not adequately address their needs. Lippincott Williams & Wilkins 2023-08-03 /pmc/articles/PMC10552969/ /pubmed/37534935 http://dx.doi.org/10.1097/HC9.0000000000000219 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Original Article Onofrio, Fernanda Zheng, Katina Xu, Cherry Chen, Shiyi Xu, Wei Vyas, Mary Bingham, Katie Patel, Keyur Lilly, Leslie Cattral, Mark Selzner, Nazia Jaeckel, Elmar Tsien, Cynthia Gulamhusein, Aliya Hirschfield, Gideon M. Bhat, Mamatha Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis |
title | Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis |
title_full | Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis |
title_fullStr | Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis |
title_full_unstemmed | Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis |
title_short | Living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis |
title_sort | living donor liver transplantation can address disparities in transplant access for patients with primary sclerosing cholangitis |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552969/ https://www.ncbi.nlm.nih.gov/pubmed/37534935 http://dx.doi.org/10.1097/HC9.0000000000000219 |
work_keys_str_mv | AT onofriofernanda livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT zhengkatina livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT xucherry livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT chenshiyi livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT xuwei livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT vyasmary livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT binghamkatie livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT patelkeyur livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT lillyleslie livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT cattralmark livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT selznernazia livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT jaeckelelmar livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT tsiencynthia livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT gulamhuseinaliya livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT hirschfieldgideonm livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis AT bhatmamatha livingdonorlivertransplantationcanaddressdisparitiesintransplantaccessforpatientswithprimarysclerosingcholangitis |